-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
In the first 20 years of the 21st century, PD-1 is undoubtedly the most successful target in the field of immunity so far, and the accompanying tumor immunotherapy has become one of the current hot tracks
(Starting in 2017, as the commercialization potential of PD-1 has been gradually confirmed, related IL-2/IL-2R product transactions have gradually become hot)
Source of information: NextPharma Global New Drug Database
In fact, IL-2 is already a relatively mature anti-cancer target.
Reference: Spolski R, et al.
As the most competitive country among PD-1 players in the world, similarly, IL-2 also has many players in the layout
Information source: NextTarget target database
For new companies entering the market, in the field of independent research and development, Hengrui Medicine currently has two IL-2 drugs under development, namely SHR-1916 and RS2102.
Like Hengrui, Cinda Biotech has adopted an independent research and development model
In the pipeline integration area, we have to look at how Junshi bought and bought.
Source of information: NextPharma Global New Drug Database
Not only at home, Junshi also chose a cooperative enterprise abroad
In less than a month, Junshi has successively obtained the development license rights for three IL-2 drugs, which can be described as vigorous and resolute
Finally, looking back and closer, Junshi’s three transactions have a total of expenditure: 306.
Note: The original text has been deleted
